Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF.

J Clin Oncol. 2017 Mar 10;35(8):826-833. doi: 10.1200/JCO.2016.70.4320. Epub 2017 Jan 17.

2.

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW.

Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.

3.

Studying navitoclax, a targeted anticancer drug, in healthy volunteers--ethical considerations and risk/benefit assessments and management.

Xiong H, Pradhan RS, Nada A, Krivoshik AP, Holen KD, Rhodes JW, Gordon GB, Humerickhouse R, Awni WM.

Anticancer Res. 2014 Jul;34(7):3739-46.

PMID:
24982396
4.

Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.

Innocenti F, Ramírez J, Obel J, Xiong J, Mirkov S, Chiu YL, Katz DA, Carr RA, Zhang W, Das S, Adjei A, Moyer AM, Chen PX, Krivoshik A, Medina D, Gordon GB, Ratain MJ, Sahelijo L, Weinshilboum RM, Fleming GF, Bhathena A.

Pharmacogenet Genomics. 2013 Jul;23(7):374-81. doi: 10.1097/FPC.0b013e3283623e81.

5.

A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients.

Ma T, Fuld AD, Rigas JR, Hagey AE, Gordon GB, Dmitrovsky E, Dragnev KH.

Chemotherapy. 2012;58(4):321-9. doi: 10.1159/000343165. Epub 2012 Nov 12.

6.

A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy.

Lalla RV, Gordon GB, Schubert M, Silverman S Jr, Hutten M, Sonis ST, LeVeque F, Peterson DE.

Support Care Cancer. 2012 Aug;20(8):1797-804. doi: 10.1007/s00520-011-1277-7. Epub 2011 Oct 1.

PMID:
21964618
7.

Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.

Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, Kang S, Linden KG, Heffernan M, Duvic M, Richmond E, Elewski BE, Umar A, Bell W, Gordon GB.

J Natl Cancer Inst. 2010 Dec 15;102(24):1835-44. doi: 10.1093/jnci/djq442. Epub 2010 Nov 29.

8.

ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature.

Luo Y, Hradil VP, Frost DJ, Rosenberg SH, Gordon GB, Morgan SJ, Gagne GD, Cox BF, Tahir SK, Fox GB.

Anticancer Drugs. 2009 Jul;20(6):483-92. doi: 10.1097/CAD.0b013e32832c0acf.

PMID:
19398903
9.

Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.

Baker LH, Rowinsky EK, Mendelson D, Humerickhouse RA, Knight RA, Qian J, Carr RA, Gordon GB, Demetri GD.

J Clin Oncol. 2008 Dec 1;26(34):5583-8. doi: 10.1200/JCO.2008.17.4706. Epub 2008 Nov 3.

PMID:
18981463
10.

Effects of repeated freeze-thaw cycles on concentrations of cholesterol, micronutrients, and hormones in human plasma and serum.

Comstock GW, Burke AE, Norkus EP, Gordon GB, Hoffman SC, Helzlsouer KJ.

Am J Epidemiol. 2008 Oct 1;168(7):827-30. doi: 10.1093/aje/kwn327. No abstract available.

PMID:
18820276
11.

A phase II study of ABT-751 in patients with advanced non-small cell lung cancer.

Mauer AM, Cohen EE, Ma PC, Kozloff MF, Schwartzberg L, Coates AI, Qian J, Hagey AE, Gordon GB.

J Thorac Oncol. 2008 Jun;3(6):631-6. doi: 10.1097/JTO.0b013e318174e01f.

12.

Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma.

Ebbinghaus S, Hussain M, Tannir N, Gordon M, Desai AA, Knight RA, Humerickhouse RA, Qian J, Gordon GB, Figlin R.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6689-95.

13.

Recommended changes to oncology clinical trial design: revolution or evolution?

Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR, Stadler WM, Berry DA, Peck CC.

Eur J Cancer. 2008 Jan;44(1):8-11. Epub 2007 Nov 5. No abstract available.

14.

Celecoxib for the prevention of sporadic colorectal adenomas.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET; APC Study Investigators.

N Engl J Med. 2006 Aug 31;355(9):873-84.

15.

The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.

Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, Lockhart AC, Medina D, Sosman J, Gordon GB, Rothenberg ML.

Clin Cancer Res. 2006 May 1;12(9):2834-40.

16.

Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.

Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ.

Clin Cancer Res. 2005 Sep 15;11(18):6615-24.

17.

Hybridization enhancement using microfluidic planetary centrifugal mixing.

Bynum MA, Gordon GB.

Anal Chem. 2004 Dec 1;76(23):7039-44.

PMID:
15571357
18.

Cancer prevention and the American Society of Clinical Oncology.

Lippman SM, Levin B, Brenner DE, Gordon GB, Aldige CR, Kramer BS, Garber JE, Hawk E, Ganz PA, Somerfield MR; Writing Committee of the ASCO Cancer Prevention Committee.

J Clin Oncol. 2004 Oct 1;22(19):3848-51. Epub 2004 Sep 7. No abstract available.

PMID:
15353541
19.

A strategy for cancer prevention: stimulation of the Nrf2-ARE signaling pathway.

Zhang Y, Gordon GB.

Mol Cancer Ther. 2004 Jul;3(7):885-93. Review.

20.

Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women.

Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE Jr, Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Key TJ, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo P, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Kuller LH, Cummings SR, Helzlsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB, Miller SR, Longcope C; Endogenous Hormones Breast Cancer Collaborative Group.

J Natl Cancer Inst. 2003 Aug 20;95(16):1218-26.

PMID:
12928347
21.

Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.

Kelloff GJ, O'Shaughnessy JA, Gordon GB, Hawk ET, Sigman CC.

Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):593-6. No abstract available.

22.

A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.

Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su LK, Sherman J, Kelloff G, Levin B, Steinbach G; FAP Study Group.

Gut. 2002 Jun;50(6):857-60.

23.

Serum dehydroepiandrosterone and dehydroepiandrosterone sulfate and risk of melanoma or squamous cell carcinoma of the skin.

Alberg AJ, Gordon GB, Genkinger JM, Hoffman SC, Selvin E, Comstock GW, Helzlsouer KJ.

Anticancer Res. 2001 Nov-Dec;21(6A):4051-4.

PMID:
11911290
24.

Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.

O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD.

Clin Cancer Res. 2002 Feb;8(2):314-46.

25.

Effects of repeated freeze-thaw cycles on concentrations of cholesterol, micronutrients, and hormones in human plasma and serum.

Comstock GW, Burke AE, Norkus EP, Gordon GB, Hoffman SC, Helzlsouer KJ.

Clin Chem. 2001 Jan;47(1):139-42. No abstract available.

26.

Granulomatous peritonitis after laparoscopic cholecystectomy mimicking pelvic endometriosis.

Merchant SH, Haghir S, Gordon GB.

Obstet Gynecol. 2000 Nov;96(5 Pt 2):830-1.

PMID:
11094226
27.

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.

Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B, Godio L, Patterson S, Rodriguez-Bigas MA, Jester SL, King KL, Schumacher M, Abbruzzese J, DuBois RN, Hittelman WN, Zimmerman S, Sherman JW, Kelloff G.

N Engl J Med. 2000 Jun 29;342(26):1946-52.

28.

Serum dehydroepiandrosterone and dehydroepiandrosterone sulfate and the subsequent risk of developing colon cancer.

Alberg AJ, Gordon GB, Hoffman SC, Comstock GW, Helzlsouer KJ.

Cancer Epidemiol Biomarkers Prev. 2000 May;9(5):517-21.

29.

COX-2 and colon cancer: potential targets for chemoprevention.

Fournier DB, Gordon GB.

J Cell Biochem Suppl. 2000;34:97-102. Review.

PMID:
10762021
30.

Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.

Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, Conti CJ.

Mol Carcinog. 1999 Aug;25(4):231-40.

PMID:
10449029
31.
32.

A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer.

Subramanyan S, Abeloff MD, Bond SE, Davidson NE, Fetting JH, Gordon GB, Kennedy MJ.

Cancer Chemother Pharmacol. 1999;43(6):497-502.

PMID:
10321510
33.

Soy, its components, and cancer prevention: a review of the in vitro, animal, and human data.

Fournier DB, Erdman JW Jr, Gordon GB.

Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):1055-65. Review. No abstract available.

34.
35.

Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers.

Kensler TW, He X, Otieno M, Egner PA, Jacobson LP, Chen B, Wang JS, Zhu YR, Zhang BC, Wang JB, Wu Y, Zhang QN, Qian GS, Kuang SY, Fang X, Li YF, Yu LY, Prochaska HJ, Davidson NE, Gordon GB, Gorman MB, Zarba A, Enger C, Muñoz A, Helzlsouer KJ, et al.

Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):127-34.

36.

Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes.

Jacobson LP, Zhang BC, Zhu YR, Wang JB, Wu Y, Zhang QN, Yu LY, Qian GS, Kuang SY, Li YF, Fang X, Zarba A, Chen B, Enger C, Davidson NE, Gorman MB, Gordon GB, Prochaska HJ, Egner PA, Groopman JD, Muñoz A, Helzlsouer KJ, Kensler TW.

Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):257-65.

37.

Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China.

Zhang BC, Zhu YR, Wang JB, Wu Y, Zhang QN, Qian GS, Kuang SY, Li YF, Fang X, Yu LY, De Flora S, Jacobson LP, Zarba A, Egner PA, He X, Wang JS, Chen B, Enger CL, Davidson NE, Gordon GB, Gorman MB, Prochaska HJ, Groopman JD, Muñoz A, Kensler TW.

J Cell Biochem Suppl. 1997;28-29:166-73. Review.

PMID:
9589363
38.

Measurement of total carbon dioxide production by means of D2O18. 1955.

Lifson N, Gordon GB, McClintock R.

Obes Res. 1997 Jan;5(1):78-84. No abstract available.

39.

Serum gonadotropins and steroid hormones and the development of ovarian cancer.

Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC, Comstock GW.

JAMA. 1995 Dec 27;274(24):1926-30.

PMID:
8568986
40.

A prospective study of endogenous hormones and breast cancer.

Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW.

Cancer Detect Prev. 1994;18(2):79-85.

PMID:
8025899
41.

Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer.

Armstrong DK, Fetting JH, Davidson NE, Gordon GB, Huelskamp AM, Abeloff MD.

Breast Cancer Res Treat. 1993 Dec;28(3):277-84.

PMID:
8018956
42.

The relationship of serum dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate.

Comstock GW, Gordon GB, Hsing AW.

Cancer Epidemiol Biomarkers Prev. 1993 May-Jun;2(3):219-21.

43.

Serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate and the risk of developing gastric cancer.

Gordon GB, Helzlsouer KJ, Alberg AJ, Comstock GW.

Cancer Epidemiol Biomarkers Prev. 1993 Jan-Feb;2(1):33-5.

44.

Hepsulfam sensitivity in human breast cancer cell lines: the role of glutathione and glutathione S-transferase in resistance.

Armstrong DK, Gordon GB, Hilton J, Streeper RT, Colvin OM, Davidson NE.

Cancer Res. 1992 Mar 15;52(6):1416-21.

45.
46.

Induction of NAD(P)H:quinone reductase in human peripheral blood lymphocytes.

Gordon GB, Prochaska HJ, Yang LY.

Carcinogenesis. 1991 Dec;12(12):2393-6.

PMID:
1660793
47.

High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer.

Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE.

J Natl Cancer Inst. 1991 Jul 3;83(13):920-6.

PMID:
1906111
48.

Serum levels of dehydroepiandrosterone and its sulfate and the risk of developing bladder cancer.

Gordon GB, Helzlsouer KJ, Comstock GW.

Cancer Res. 1991 Mar 1;51(5):1366-9.

49.
50.

Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography.

Herrington DM, Gordon GB, Achuff SC, Trejo JF, Weisman HF, Kwiterovich PO Jr, Pearson TA.

J Am Coll Cardiol. 1990 Nov;16(6):862-70.

Supplemental Content

Loading ...
Support Center